𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Sleep and daily functioning during androgen deprivation therapy for prostate cancer

✍ Scribed by L.J. HANISCH; N.S. GOONERATNE; K. SOIN; P.R. GEHRMAN; D.J. VAUGHN; J.C. COYNE

Book ID
108710902
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
77 KB
Volume
20
Category
Article
ISSN
0961-5423

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Pathologic changes associated with andro
Pathologic changes associated with androgen deprivation therapy for prostate cancer
✍ William M. Murphy; Mark S. Soloway; George H. Barrows πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 934 KB

Prostate glands exposed to androgen deprivation with leuprolide -+ flutamide were evaluated for pathologic changes which might be related to therapy. Comparing pretreatment and posttreatment tissue by visual discrimination using light microscopic study revealed treatment-related alterations in the s

Denosumab and changes in bone turnover m
Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer
✍ Matthew R Smith; Fred Saad; Blair Egerdie; Paul Sieber; Teuvo LJ Tammela; Benjam πŸ“‚ Article πŸ“… 2011 πŸ› American Society for Bone and Mineral Research 🌐 English βš– 127 KB

## Abstract Androgen deprivation therapy (ADT) for prostate cancer increases fracture risk, decreases bone mineral density, and increases bone turnover markers (BTMs) including serum type 1 C‐telopeptide (sCTX), tartrate‐resistant alkaline phosphatase 5b (TRAP‐5b), and procollagen‐1 N‐terminal telo